{
    "BJOG - 2019 - Chu - Maternal Collapse in Pregnancy and the Puerperium.pdf": "Diagnosis:\n- Maternal Collapse in Pregnancy and the Puerperium\n- Anaphylaxis\n- Aortocaval compression\n- Difficult intubation\n- Increased risk of aspiration\n- Maternal cardiac arrest\n- Concealed haemorrhage\n- Maternal cardiopulmonary arrest\n- Perimortem caesarean section (PMCS)\n- Maternal collapse secondary to antepartum haemorrhage\n- Massive placental abruption\n- Massive pulmonary embolism\n- Amniotic fluid embolism (AFE)\n- Coagulopathy\n- Septic shock\n- Magnesium toxicity\n- Local anaesthetic toxicity\n- Eclampsia\n- Intracranial haemorrhage\n- Anaphylaxis\n\nInvestigation:\n- Obstetric modified early warning score chart\n- Mast cell tryptase levels\n- Abdominal ultrasound\n\nManagement:\n- Resuscitation Council (UK) guidelines\n- Basic life support\n- Manual displacement of the uterus\n- Left lateral tilt of the woman\n- Intubation\n- Supplemental high flow oxygen\n- Bag and mask ventilation\n- Chest compressions\n- Wide-bore cannulae\n- Volume replacement\n- Defibrillation\n- PMCS\n- Intravenous tranexamic acid\n- Recombinant factor VII\n- Lipid rescue\n- Intralipid/C22620%\n- 1:1000 adrenaline 500 micrograms (0.5 ml) intramuscularly\n- Annual formal multidisciplinary training in generic life support\n- Small group multidisciplinary interactive practical training",
    "BJOG - 2019 - Thomson - Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24 0 Weeks of.pdf": "Diagnosis:\n1. Preterm Prelabour Rupture of Membranes (PPROM)\n2. Chorioamnionitis\n\nInvestigation:\n1. Sterile speculum examination\n2. Insulin-like growth factor-binding protein 1 (IGFBP-1) test\n3. Placental alpha microglobulin-1 (PAMG-1) test\n4. Maternal blood tests (C-reactive protein and white cell count)\n5. Fetal heart rate monitoring\n\nManagement:\n1. Antibiotics (preferably erythromycin) for 10 days or until the woman is in established labour\n2. Corticosteroids for women who have PPROM between 24+0 and 33+6 weeks\u2019 gestation\n3. Expectant management until 37+0 weeks for women whose pregnancy is complicated by PPROM after 24+0 weeks of gestation and who have no contraindications to continuing the pregnancy\n4. Intravenous magnesium sulfate for women who have PPROM and are in established labour or having a planned preterm birth within 24 hours, between 24+0 and 29+6 weeks of gestation.",
    "BJOG - 2016 -  - Diagnosis and Management of Ectopic Pregnancy.pdf": "1. Ectopic Pregnancy\n2. Tubal Pregnancy\n3. Transvaginal Ultrasound\n4. Serum progesterone level\n5. Serum beta-human chorionic gonadotrophin (b-hCG) level\n6. Cervical Pregnancy\n7. Caesarean Scar Pregnancy\n8. Interstitial Pregnancy\n9. Cornual Pregnancy\n10. Ovarian Pregnancy",
    "BHIVA-Pregnancy-guidelines-2020-3rd-interim-update.pdf.pdf": "- Diagnosis: HIV\n- Investigation: Antiretroviral therapy (ART)\n- Management: BHIVA guidelines on the management of HIV in pregnancy and postpartum, Infant post-exposure prophylaxis (PEP), Treatment with tenofovir DF, raltegravir, rilpivirine, dolutegravir, elvitegravir and cobicistat, Psychosocial care, Breastfeeding advice, Contraception, Cervical cytology, Testing of partner and/or older children.\n- Other medical terms: Elite controllers, Preterm delivery (PTD), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Chorioamnionitis and BV, Pneumocystis pneumonia (PCP) prophylaxis, Immunisation.",
    "BJOG - 2016 -  - Management of Premenstrual Syndrome.pdf": "Diagnosis:\n1. Premenstrual Syndrome (PMS)\n\nInvestigation:\n1. Symptom diary\n2. Gonadotrophin-releasing hormone (GnRH) analogues\n3. Daily Record of Severity of Problems (DRSP) charting\n4. Dual-energy X-ray absorptiometry (DEXA)\n\nManagement:\n1. Combined oral contraceptives (COCs)\n2. Vitamin B6\n3. Selective serotonin reuptake inhibitors (SSRIs)\n4. Cognitive behavioural therapy (CBT)\n5. Hormonal medical management\n6. Drospirenone-containing COCs\n7. Percutaneous estradiol\n8. Transdermal estrogen\n9. Levonorgestrel-releasing intrauterine system (LNG-IUS)\n10. Micronised progesterone\n11. Danazol\n12. GnRH analogues\n13. Add-back hormone therapy\n14. Hormone replacement therapy (HRT)\n15. Selective SSRIs\n16. Spironolactone\n17. Hysterectomy and bilateral oophorectomy\n18. Endometrial ablation\n19. Bilateral oophorectomy\n20. Surgical treatment\n21. Exercise\n22. Integrated holistic approach\n23. Complementary therapies\n24. Progesterone and progestogen preparations\n25. Prepregnancy counselling.",
    "BJOG - 2018 - Denison - Care of Women with Obesity in Pregnancy.pdf": "Diagnosis:\n1. Obesity in pregnancy\n2. Hypertensive complications\n3. Fetal macrosomia\n4. Vitamin D deficiency\n5. Gestational diabetes\n6. Pre-eclampsia\n7. Venous thromboembolism (VTE)\n8. Mental health problems\n9. Chromosomal anomalies\n10. Structural anomalies\n11. Small-for-gestational-age fetus\n12. Postpartum haemorrhage (PPH)\n\nInvestigation:\n1. Weight and BMI measurement\n2. Nutritional supplements\n3. Folic acid supplementation\n4. Vitamin D supplementation\n5. Antenatal care\n6. Risk assessment for anaesthetics\n7. Risk assessment for prevention of pressure sores\n8. Screening for gestational diabetes\n9. Screening for hypertensive complications of pregnancy\n10. Screening for venous thromboembolism\n11. Screening for mental health problems\n12. Antenatal screening for chromosomal anomalies\n13. Screening for structural anomalies\n14. Fetal monitoring\n15. Monitoring during labour\n16. Monitoring post dates in women with obesity\n\nManagement:\n1. Weight loss before conception and between pregnancies\n2. Dietetic advice\n3. Anti-obesity drugs\n4. Anaesthetic management plan for labour and birth\n5. Management of hypertensive complications\n6. Management of venous thromboembolism\n7. Planning labour and birth\n8. Induction of labour\n9. Caesarean section\n10. Vaginal birth after caesarean (VBAC)\n11. Active management of the third stage of labour\n12. Surgical techniques for performing caesarean section on obese women.",
    "antenatal-care-pdf-66143709695941.pdf": "Diagnosis: N/A\n\nInvestigation: \"Taking and r ecording the w oman 's histor y\", \"her medical hist ory, obst etric hist ory and f amily hist ory\", \"previous or curr ent mental healt h concerns\", \"current and r ecent medicines\", \"allergies\", \"her occupation\", \"her f amily and home situation\", \"other people who ma y be in volved in t he car e of t he bab y\", \"contact details f or her par tner and her ne xt\"\n\nManagement: \"Offer a first ant enatal (booking) appointment wit h a midwif e to tak e place by 10+0  weeks of pr egnancy\", \"Plan 10  routine ant enatal appointment s wit h a midwif e or doct or for nullipar ous w omen\", \"Plan 7  routine ant enatal appointment s wit h a midwif e or doct or for parous w omen\", \"Offer additional or longer ant enatal appointment s if needed\", \"Ensur e that r eliable int erpreting ser vices ar e available when needed\", \"Those r esponsible f or planning and deliv ering ant enatal ser vices should aim t o provide continuity of car er\", \"Ensur e that t here is eff ectiv e and pr ompt communication betw een healt hcare professionals who ar e involved in t he w oman's car e during pregnancy\", \"involve par tners accor ding t o the w oman's wishes\", \"inform t he w oman t hat she is w elcome t o bring a par tner t o ant enatal appointment s and classes\", \"Consider arranging t he timing of ant enatal classes so t hat t he pr egnant woman's par tner can att end, if t he w oman wishes\", \"When planning and deliv ering ant enatal ser vices, ensur e that t he environment is w elcoming f or par tners as w ell as pr egnant w omen\".",
    "BJOG - 2017 -  - Management of Inherited Bleeding Disorders in Pregnancy.pdf": "Diagnosis: Inherited Bleeding Disorders, Haemophilia, von Willebrand disease (VWD)\n\nInvestigation: Genetic counselling, prenatal diagnosis (PND), preimplantation genetic diagnosis, fetal sex determination by free fetal DNA analysis, chorionic villus sampling, third trimester amniocentesis, diagnostic testing of the neonate, cord blood sampling, cranial ultrasound (US), cranial magnetic resonance imaging (MRI), VWF antigen levels and activity, and factor VIII levels check.\n\nManagement: Management of Inherited Bleeding Disorders in Pregnancy, prepregnancy management, antepartum management, postpartum management, neonatal management, haemostatic management during labour, analgesia and anaesthesia management, multidisciplinary approach, treatment with DDAVP, Recombinant factor VIII, Recombinant factor IX, Tranexamic acid, vitamin K administration, short-term primary prophylaxis.",
    "BJOG - 2017 -  - Management of Breech Presentation.pdf": "Diagnosis: Breech Presentation\n\nInvestigation: \n1. External cephalic version (ECV)\n2. Assessment for risk factors for a poorer outcome in planned vaginal breech birth\n3. Ultrasound to estimate the position of the fetal neck and legs, and the fetal weight \n4. Continuous electronic fetal monitoring \n\nManagement: \n1. Counselling on the risks and benefits of planned vaginal breech delivery versus planned caesarean section\n2. Individualised assessment of the long-term risks of caesarean section based on their individual risk profile and reproductive intentions\n3. Planned caesarean section for breech presentation in spontaneous preterm labour is not recommended\n4. Labour with a preterm breech should be managed as with a term breech\n5. Simulation equipment should be used to rehearse the skills that are needed during vaginal breech birth by all doctors and midwives\n6. Guidance for the case selection and management of vaginal breech birth should be developed in each department by the healthcare professionals who supervise such births\n7. Departments should consider developing a checklist to ensure comprehensive counselling of the woman regarding planned mode of delivery for babies presenting by the breech.",
    "BJOG - 2016 -  - Management of Monochorionic Twin Pregnancy.pdf": "Diagnosis: \n- Monochorionic Twin Pregnancy\n- Twin-to-twin transfusion syndrome (TTTS)\n- Twin anaemia-polycythaemia sequence (TAPS)\n- Selective growth restriction (sGR)\n- Single twin demise\n- Fetal anaemia\n- Fetal death\n- Neurological abnormality\n- Discordant abnormalities\n\nInvestigation: \n- Prenatal ultrasound\n- Ultrasound examination between 11+0weeks and 13+6weeks of gestation\n- Chorionicity determination\n- Photographic record of ultrasound\n- Neuploidy screening\n- Nuchal translucency measurements\n- First trimester serum markers\n- Second trimester screening by the quadruple test\n- Noninvasive prenatal testing\n- Detailed ultrasound scan between 18 and 20+6weeks of gestation\n- Fetal ultrasound assessment every 2 weeks from 16+0weeks onwards\n- Liquor volume assessment\n- Umbilical artery pulsatility index (UAPI) measurement\n- Fetal biometry\n- Middle cerebral artery peak systolic velocity (MCA PSV) measurement\n- Umbilical artery Doppler evaluation\n- Fetal magnetic resonance imaging of the brain\n\nManagement: \n- Regular ultrasound examinations\n- Referral to a specialist in case of doubt in chorionicity diagnosis\n- Fetoscopic laser ablation for TTTS\n- Regular ultrasound assessment post TTTS treatment\n- Delivery of monochorionic twin pregnancies between 34+0and 36+6weeks of gestation\n- Selective reduction in cases of early-onset sGR\n- Fetal Doppler assessment in sGR\n- Delivery planning in sGR\n- Informing parents about potential adverse perinatal outcomes\n- Assessment in a fetal medicine centre in case of single fetal death\n- Measurement of fetal MCA PSV in case of fetal anaemia\n- Elective delivery from 36+0weeks with the administration of antenatal steroids\n- Vaginal birth of monochorionic diamniotic twins\n- Caesarean section between 32+0and 34+0weeks for MCMA twins\n- Selective reduction in higher order pregnancies\n- Increased ultrasound surveillance in higher order pregnancies\n- Referral for assessment and counselling in a fetal medicine centre in case of discordant abnormalities\n- Karyotyping of monochorionic twins.",
    "BJOG - 2017 -  - Prevention of Early\u2010onset Neonatal Group B Streptococcal Disease.pdf": "Diagnosis:\n1. Group B Streptococcal (GBS) colonisation\n2. Early-onset GBS (EOGBS) disease\n3. GBS bacteriuria\n4. GBS urinary tract infection\n5. Early-onset neonatal infection\n6. Severe allergy to penicillin\n7. Clinical signs of EOGBS disease\n\nInvestigation:\n1. Bacteriological screening for GBS\n2. Bacteriological testing in late pregnancy\n3. Testing for GBS carrier status\n4. Testing for GBS carriage\n5. Polymerase chain reaction or other near-patient testing at the onset of labour\n6. Swab from the lower vagina and the anorectum for GBS carrier status\n7. Enriched culture medium tests for GBS carriage\n8. Evaluation at birth for clinical indicators of neonatal infection\n\nManagement:\n1. Intrapartum antibiotic prophylaxis (IAP)\n2. Treatment of GBS urinary tract infection during pregnancy\n3. Management of GBS colonisation in women who decline IAP\n4. Management of newborn baby with concerns about early-onset neonatal infection\n5. Treatment of babies with clinical signs of EOGBS disease with penicillin and gentamicin\n6. Breastfeeding irrespective of GBS status\n7. Management of term labour (including rupture of membranes) to reduce the risk of EOGBS disease\n8. Management of preterm labour (including rupture of membranes) to reduce the risk of EOGBS disease\n9. Antibiotic prophylaxis for women undergoing planned caesarean section\n10. Management of term babies whose mothers have received adequate IAP\n11. Monitoring of well babies at risk of EOGBS disease whose mothers have not received adequate IAP\n12. Management of the baby of a mother who has had a previous baby with GBS disease.",
    "BJOG - 2017 -  - External Cephalic Version and Reducing the Incidence of Term Breech Presentation.pdf": "Diagnosis:\n- Term Breech Presentation\n- Noncephalic birth\n\nInvestigation:\n- External Cephalic Version (ECV)\n- ECV success prediction models\n- Use of tocolysis with betamimetics\n- Use of regional analgesia or neuraxial blockade\n- Testing for fetomaternal haemorrhage\n\nManagement:\n- ECV should be offered at term from 37+0 weeks of gestation\n- In nulliparous women, ECV may be offered from 36+0 weeks of gestation\n- ECV should only be performed by a trained practitioner or by a trainee working under direct supervision\n- ECV should be performed where facilities for monitoring and surgical delivery are available\n- Following ECV, Electronic Fetal Monitoring (EFM) is recommended\n- Women undergoing ECV who are D negative should be offered anti-D\n- Consideration of the use of moxibustion for breech presentation at 33 \u201335 weeks of gestation, under the guidance of a trained practitioner\n- No evidence that postural management alone promotes spontaneous version to cephalic presentation.",
    "BJOG - 2016 -  - Prevention and Management of Postpartum Haemorrhage.pdf": "Diagnosis:\n- Postpartum Haemorrhage (PPH)\n- Antenatal anaemia\n- Secondary PPH\n\nInvestigation:\n- Full blood count\n- Coagulation screen, including fibrinogen\n- Renal and liver function for baseline\n- Vaginal microbiology (high vaginal and endocervical swabs)\n- Pelvic ultrasound\n\nManagement:\n- Use of prophylactic uterotonics\n- Use of oxytocin for prophylaxis in the third stage of labour\n- Use of intravenous tranexamic acid to reduce blood loss\n- Use of intrauterine balloon tamponade\n- Use of surgical interventions such as brace suture technique and hysterectomy\n- Use of blood transfusion and blood components like fresh frozen plasma (FFP), fibrinogen and platelets\n- Use of antimicrobial therapy for suspected endometritis\n- Surgical evacuation of retained placental tissue\n- Use of recombinant factor VIIa (rFVIIa) therapy\n- Multidisciplinary protocol for the management of PPH\n- Training for PPH management\n- Formal clinical incident review for cases of PPH involving a blood loss of greater than 1500 ml\n- Accurate documentation of a delivery with PPH\n- Debriefing sessions for the woman and her birthing partner/s.",
    "BJOG - 2016 -  - Management of Bladder Pain Syndrome.pdf": "Diagnosis:\n- Bladder Pain Syndrome (BPS)\n- Chronic pain syndrome\n- Urological malignancy\n- Coexisting BPS and overactive bladder\n- Stress urinary incontinence\n- Voiding dysfunction\n\nInvestigation:\n- Initial clinical assessment\n- Medical history\n- Physical examination\n- Bladder diary (frequency volume chart)\n- Food diary\n- Urine test for urinary tract infection, urinary ureaplasma and chlamydia\n- Urine cytology\n- Cystoscopy\n- Bladder biopsies\n- Hydrodistention\n- Potassium sensitivity test\n- Urodynamic assessment\n- Urinary biomarkers\n\nManagement:\n- Management of chronic pain\n- Dietary modification\n- Stress management\n- Regular exercise\n- Analgesia for pelvic or bladder pain\n- Acupuncture\n- Oral amitriptyline or cimetidine\n- Intravesical treatments (lidocaine, hyaluronic acid, botulinum toxin A, dimethyl sulfoxide, heparin, chondroitin sulfate)\n- Cystoscopic fulguration and laser treatment\n- Transurethral resection of lesions\n- Neuromodulation (nerve stimulation)\n- Oral cyclosporin A\n- Cystoscopy with or without hydrodistension\n- Major surgery\n- Referral to a physiotherapist\n- Psychological support or counselling\n- Referral to a multidisciplinary team (MDT)\n- Support groups\n- Long-term management and prognosis\n- Pregnancy considerations (oral amitriptyline, intravesical heparin, DMSO)"
}